NZ591181A - Organoarsenic compounds and methods for the treatment of cancer - Google Patents

Organoarsenic compounds and methods for the treatment of cancer

Info

Publication number
NZ591181A
NZ591181A NZ591181A NZ59118109A NZ591181A NZ 591181 A NZ591181 A NZ 591181A NZ 591181 A NZ591181 A NZ 591181A NZ 59118109 A NZ59118109 A NZ 59118109A NZ 591181 A NZ591181 A NZ 591181A
Authority
NZ
New Zealand
Prior art keywords
cancer
treatment
methods
lymphoma
formula
Prior art date
Application number
NZ591181A
Inventor
Brian Eric Schwartz
Jonathan Lewis
Philip B Komarnitsky
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Publication of NZ591181A publication Critical patent/NZ591181A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein is a method for treating in a non-human animal a lymphoma selected from peripheral T-cell lymphoma (PTCL), diffuse large B-cell, marginal zone lymphoma, and Hodgkin's nodular sclerosis, comprising administering a compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined in the specification. In one embodiment, formula (I) represents L-(+)-2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid.
NZ591181A 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer NZ591181A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20
PCT/US2009/053858 WO2010021928A1 (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ591181A true NZ591181A (en) 2012-09-28

Family

ID=41707414

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591181A NZ591181A (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Country Status (19)

Country Link
US (4) US20110269697A1 (en)
EP (2) EP2321012B1 (en)
JP (5) JP5933896B2 (en)
KR (3) KR20170103023A (en)
CN (2) CN102149432A (en)
AU (1) AU2009282972A1 (en)
BR (1) BRPI0918407A2 (en)
CA (1) CA2734650A1 (en)
DK (2) DK3388111T3 (en)
ES (2) ES2901426T3 (en)
HK (2) HK1254607A1 (en)
IL (1) IL211153A0 (en)
MX (1) MX2011001800A (en)
NZ (1) NZ591181A (en)
PT (2) PT3388111T (en)
RU (1) RU2534606C2 (en)
SG (3) SG10201403869TA (en)
WO (1) WO2010021928A1 (en)
ZA (1) ZA201101216B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160304546A1 (en) * 2013-12-05 2016-10-20 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
CN104151397A (en) * 2014-07-03 2014-11-19 北京大学 Novel thiabicyclo organic arsenide compound and synthesis method thereof, as well as application in anti-tumor field
JP6413969B2 (en) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 Dispersion for forming solar shading body and solar shading body using the dispersion
JPWO2019220961A1 (en) * 2018-05-18 2020-05-28 ソレイジア・ファーマ株式会社 Crystalline form of darinaparcin alkali metal salt and/or inorganic acid addition salt and preparation thereof
CN113408945B (en) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 Method and device for detecting purity of flue-cured tobacco, electronic equipment and storage medium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
PT1621077E (en) 1997-10-15 2008-11-04 Polarx Biopharmaceuticals Inc Phamaceutical compositions comprising arsenic trioxide for the treatment of a tumor of the central nervous system
DK2255800T3 (en) 1997-11-10 2013-02-04 Sloan Kettering Inst Cancer Arsenic trioxide for use in the treatment of leukemia
CN1233476A (en) 1998-04-24 1999-11-03 陆道培 Medicine for treating acute leukemia, and method for preparing same
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
ES2261399T3 (en) 2000-04-26 2006-11-16 Oregon Health Sciences University ADMINISTRATION OF A CHEMIOPROTECTOR COMPOUND CONTAINING TIOL.
DE10132625A1 (en) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Process, computer program product and device system for visually checking image data
CA2472633C (en) 2002-01-07 2014-07-08 Ralph A. Zingaro S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201350113A (en) * 2004-07-16 2013-12-16 Texas A & M Univ Sys Organic arsenic compounds, uses of the same in treating cancer and pharmaceutical compositions comprising the same
EP1919564B1 (en) 2005-07-29 2014-11-26 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
EP1979368B1 (en) * 2006-01-13 2014-12-24 The Texas A&M University System Compounds and methods for the treatment of cancer
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
ES2392737T3 (en) * 2007-11-02 2012-12-13 Ziopharm Oncology, Inc. Combined therapy with organic arsenical compounds
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
HK1254607A1 (en) 2019-07-26
JP2017002081A (en) 2017-01-05
US20150231107A1 (en) 2015-08-20
BRPI0918407A2 (en) 2015-11-24
PT2321012T (en) 2019-01-11
CN104800828A (en) 2015-07-29
JP2014148552A (en) 2014-08-21
CN102149432A (en) 2011-08-10
ES2703740T3 (en) 2019-03-12
SG10201403869TA (en) 2014-10-30
EP3388111B1 (en) 2021-09-29
DK3388111T3 (en) 2021-12-06
ES2901426T3 (en) 2022-03-22
JP2012500271A (en) 2012-01-05
EP2321012B1 (en) 2018-10-10
AU2009282972A1 (en) 2010-02-25
EP2321012A4 (en) 2011-10-05
KR20110058818A (en) 2011-06-01
JP2018039853A (en) 2018-03-15
JP6315841B2 (en) 2018-04-25
DK2321012T3 (en) 2018-12-03
CA2734650A1 (en) 2010-02-25
KR20180103194A (en) 2018-09-18
US10842769B2 (en) 2020-11-24
HK1212218A1 (en) 2016-06-10
RU2534606C2 (en) 2014-11-27
EP3388111A1 (en) 2018-10-17
ZA201101216B (en) 2011-10-26
SG10201810450QA (en) 2018-12-28
PT3388111T (en) 2021-12-23
US20110269697A1 (en) 2011-11-03
KR20170103023A (en) 2017-09-12
US20210038556A1 (en) 2021-02-11
JP5976036B2 (en) 2016-08-23
US20210038557A1 (en) 2021-02-11
SG10201810449XA (en) 2018-12-28
JP5933896B2 (en) 2016-06-15
EP2321012A1 (en) 2011-05-18
RU2011110392A (en) 2012-09-27
US11324714B2 (en) 2022-05-10
WO2010021928A1 (en) 2010-02-25
IL211153A0 (en) 2011-04-28
JP2015120755A (en) 2015-07-02
MX2011001800A (en) 2011-04-04
US11324713B2 (en) 2022-05-10

Similar Documents

Publication Publication Date Title
MXPA05009694A (en) Methods of improving skin quality.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
TW200744586A (en) Therapeutic compounds
GB0318447D0 (en) Therapeutic agents
BRPI0507984A (en) compound or a salt thereof, process for producing a compound, medicament, methods for antagonizing angiotensin ii in a mammal, improving insulin resistance in a mammal, and preventing or treating circulatory disease in a mammal, and, use of the compound
WO2009050506A3 (en) Combination 059
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
PL1613315T3 (en) Quinoline-2-one-derivatives for the treatment of airways diseases
NZ545935A (en) Method of treating cancer with HDAC inhibitors
HK1091481A1 (en) Therapeutic agents useful for treating pain
MX2009005649A (en) Treatment for multiple myeloma.
NZ591181A (en) Organoarsenic compounds and methods for the treatment of cancer
UA96777C2 (en) Phenylpropionamide compounds and use thereof as opioid agonists
GB0207495D0 (en) Organic compounds
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
ATE401087T1 (en) COMPOUNDS FOR PAIN TREATMENT
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
MY183063A (en) Seed treatment agent and method for protecting plant
GB0416508D0 (en) Therapeutic agents
ATE437855T1 (en) (4,5,6,7-TETRAHYDRO-1H-INDOL-7-YL)ACETIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2007003790A (en) Treatment method.
DE60325965D1 (en) FOR THE TREATMENT BZW. PREVENTION OF PAIN RELATED TRIAZASPIRO COMPOUNDS
PL1648473T3 (en) Single dose fast dissolving azithromycin
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 AUG 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130504

LAPS Patent lapsed